Septal ablation, a valid alternative for obstructive hypertrophic cardiomyopathy

Original title: Survival of Patients ≤50 Years Alter Alcohol Septal Ablation for Hypertrofic Obstructive Cardiomyopathy. Reference: Josef Veselka, et al. Canadian Journal of Cardiology 2014,30:634-638

Treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM) is the surgical septal myomectomy nevertheless, currently arose several studies reporting a favourable evolution and comparable to surgery with septal ablation (AS). 75 patients under 50 years of age with HCM, 85 procedures were performed. The primary endpoint was all-cause mortality, and the secondary was all-cause mortality or defibrillator implant.

Average age of the population was 42 ± 7 years all symptomatic with a gradient of 73 ± 38 mmHg and the basal septum thickness of 23 ± 6 mm. Post procedure, 8% had complete AV block and 2.7% transient AV block with a need for permanent pacemaker of 6.7%. Follow-up was performed in all patients at 5.1 years showing significant improvement in functional class associated with a fall in the gradient outflow tract and decreased thickness in the basal septum.

Four patients died during follow-up (1 to 30 days by sudden death, 1 by stroke, 1 from gastrointestinal bleeding and 1 for cancer), only two were attributed to the underlying disease. Survival rates at 1, 3 and 5 years were 97%, 94%, and 94%, respectively, not being able to identify predictors of mortality in the multivariate analysis. The risk of death or need for a defibrillator was not associated with post septal ablation gradient.

Conclusion: 

This study in patients with obstructive hypertrophic cardiomyopathy (HCM) under 50 years who received septal ablation suggests a low risk of death from any cause or defibrillator implant in the long-term monitoring. 

Editorial comment 

Myomectomy remains the best strategy for those patients who are operated; however, this study showed a favourable evolution and comparable to surgery in young people; septal ablation is a less aggressive behaviour. More research is needed. 

Courtesy Dr. Carlos Fava
Interventional cardiologist
Favaloro Foundation
Argentina

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...